Free Trial
OTCMKTS:MCUJF

Medicure Q3 2024 Earnings Results & Report

Medicure logo
$2.76 -0.04 (-1.43%)
As of 10/14/2026 03:58 PM Eastern

Medicure reported Q3 2024 earnings on November 25, 2024. The company reported EPS of $0.05.

Earnings Announcement Details

Quarter
Q3 2024
Time
After Market Closes

Medicure EPS Results

Actual EPS
$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Medicure's next earnings date is estimated for Thursday, November 19, 2026, based on past reporting schedules.

Conference Call Resources

Medicure Q3 2024 Earnings FAQ

Medicure (OTCMKTS:MCUJF) reported earnings of $0.05 per share for Q3 2024. The report was announced on Monday, November 25, 2024.

Medicure's next earnings date is estimated for Thursday, November 19, 2026. MarketBeat tracks confirmed and estimated earnings dates for Medicure on the company's earnings history page.

Medicure Earnings Headlines

MEDICURE : ANNOUNCES GRANT OF STOCK OPTIONS
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.tc pixel
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF) is a Canadian specialty pharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company is headquartered in Winnipeg, Manitoba, and has concentrated its commercial activities on products intended for use in hospital and acute-care settings.

Medicure’s principal product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used in the management of certain patients with acute coronary syndrome and other cardiovascular conditions. The product is designed to inhibit platelet aggregation and is marketed primarily through Medicure’s U.S. operations, with the company also pursuing opportunities in other markets where appropriate.

Medicure has historically maintained a focus on cardiovascular drug development, commercialization, and licensing. The company is led by Dr. Albert D. Friesen, who has served as its president and chief executive officer. Medicure’s shares trade in Canada and in the United States under the symbol MCUJF.

View Medicure Profile